专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20230049974A1 FINGOLIMOD EXTENDED RELEASE INJECTABLE SUSPENSION 有权
公开(公告)号：US20230049974A1
公开(公告)日：2023-02-16
申请号：US17788297
申请日：2021-01-04
申请人： SHILPA MEDICARE LIMITED
发明人： KIRAN KRISHNAPPA JADHAV , SREENIVASA REDDY
IPC分类号： A61K31/137 , A61K9/00 , A61K47/38
摘要： The present invention relates to an injectable composition for extended release of fingolimod comprising a suspension of at least about 0.5 mg/ml of fingolimod, wherein fingolimod release is for at least 7 days and the process for preparation thereof.

2. 发明授权

US10993934B2 Topical compositions of dutasteride 有权
公开(公告)号：US10993934B2
公开(公告)日：2021-05-04
申请号：US16485152
申请日：2018-06-18
申请人： SHILPA MEDICARE LIMITED
发明人： Rajendar Medishetty , Agadihiremath Thippeswamy , Sreenivasa Reddy , Shivakumar Pradeep
IPC分类号： A61K31/44 , A61K31/225 , A61K31/435 , A61P17/14 , A61K9/00 , A61K47/10 , A61K47/14 , A61K47/44
摘要： The present invention relates to a composition for topical application for preventing hair loss, androgenic alopecia (AA) and stimulating hair growth having dutasteride. The composition for topical application for preventing hair loss and stimulating hair growth according to the present invention provides equal or superior hair loss prevention and hair growth stimulating effects while using much smaller dosage than the conventional compositions (oral dosage form) which use finasteride and dutasteride.

3. 发明申请

US20180334457A1 SUBSTANTIALLY PURE VEMURAFENIB AND ITS SALTS 审中-公开
公开(公告)号：US20180334457A1
公开(公告)日：2018-11-22
申请号：US15990711
申请日：2018-05-28
申请人： PUROHIT PRASHANT , NAGNNATH KOKARE , VEERA REDDY YENIREDDY , CHATURVEDI AKSHAY KANT
发明人： PUROHIT PRASHANT , NAGNNATH KOKARE , VEERA REDDY YENIREDDY , CHATURVEDI AKSHAY KANT
IPC分类号： C07D471/04 , A61K31/437
摘要： The present invention relates to a process for the preparation substantially pure propane-1-sulfonicacid-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide or Vemurafenib of Formula (I). The present invention further relates to a process for the preparation substantially pure propane-1-sulfonic acid-{3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3 -b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide trifluoro methane sulfonic acid salt or Vemurafenib triflate of Formula (VII)

4. 发明申请

US20170204062A1 PROCESS FOR THE PREPARATION OF REGORAFENIB AND ITS CRYSTALLINE FORMS 审中-公开
公开(公告)号：US20170204062A1
公开(公告)日：2017-07-20
申请号：US15324683
申请日：2015-07-06
申请人： SHILPA MEDICARE LIMITED
发明人： SRIRAM RAMPALLI , LAV KUMAR UPALLA , KRISHNA KUMAR RAMACHANDRULA , PRASHANT PUROHIT , CHATURVEDI AKSHAY KANT
IPC分类号： C07D213/81
CPC分类号： C07D213/81
摘要： The present invention relates to a process for the preparation of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide or Regorafenib (I). The present invention further relates to a process for the purification of 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide or Regorafenib (I) to provide highly pure material.The present invention further relates to a process for the preparation stable crystalline material of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methyl pyridine-2-carboxamide or Regorafenib (I) useful in the preparation of pharmaceutical compositions for the treatment of cancer.

5. 发明授权

US09593083B2 Crystalline erlotinib hydrochloride process 有权
标题翻译：结晶埃洛替尼盐酸盐工艺
公开(公告)号：US09593083B2
公开(公告)日：2017-03-14
申请号：US14418449
申请日：2013-08-14
申请人： Shilpa Medicare Limited
发明人： Vimal Kumar Shrawat , Prashant Purohit , Rafiuddin Dr. , Vinod Kumar Singh , Akshay Kant Chaturvedi
IPC分类号： C07D239/94
CPC分类号： C07D239/94 , C07B2200/13
摘要： The present invention provides process for preparation of Crystalline Erlotinib HCl (I) Form-SE characterized by X-ray powder diffraction pattern comprising at least 5 characteristic 2θ° peaks selected from the XRPD peak set of 5.60, 10.00, 11.40, 13.00, 13.50, 15.20, 18.40, 20.65, 21.86, 23.5, 31.80, 32.13, 32.80, 34.40±0.20 2θ°, DSC isotherm comprising the endothermic peaks ranging between 213 to 217° C. (Peak −1) and 225 to 235° C. (Peak −2) and IR absorption characteristic peaks at approximately 3278 cm−1, 1948 cm−1, 1871 cm−1, 1632 cm−1, 1164 cm−1, 1024 cm−1, 940 cm−1 and 742 cm−1 useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment cancer.
摘要翻译：本发明提供了制备结晶埃洛替尼（I）形式SE的方法，其特征在于X射线粉末衍射图，其包含至少5个特征2＆amp; tt;峰，其选自XRPD峰组5.60,10.00,11.40,13.00,13.50 ，15.20，18.40，20.65，21.86，23.5，31.80，32.13，32.80，34.40±0.20 2;该等温线包含213-217℃（峰-1）和225-235℃之间的吸热峰。（峰-2）和IR吸收特征峰在大约3278cm-1,1948cm -1，1871cm -1，1632cm -1，1164cm -1，1024cm -1，940cm -1和742cm -1， 1可用作用于治疗癌症的药物组合物中的活性药物成分。

6. 发明授权

US09266816B2 Fingolimod polymorphs and their processes 有权
标题翻译：芬戈莫德多晶型物及其工艺
公开(公告)号：US09266816B2
公开(公告)日：2016-02-23
申请号：US13635207
申请日：2011-08-29
申请人： Vimal Kumar Shrawat , Veereshappa , Vinod Kumar Singh , Prashant Purohit
发明人： Vimal Kumar Shrawat , Veereshappa , Vinod Kumar Singh , Prashant Purohit
IPC分类号： C07C213/10 , C07C215/10 , C07C215/28
CPC分类号： C07C213/10 , C07B2200/13 , C07C215/28
摘要： The present invention provides crystalline polymorphic forms of Fingolimod HCl (I) and processes for preparation thereof.The application provides processes for preparation of crystalline polymorphic forms-α, β and μ substantially free from process related impurities. The crystalline polymorphic forms of Fingolimod HCl (I) obtained by the processes according to the present invention having an XRDP pattern as per FIGS. 1, 3 and 5, which are useful as active pharmaceutical ingredient in pharmaceutical compositions for the treatment or prevention of autoimmune related disorder including multiple sclerosis.
摘要翻译：本发明提供了芬戈莫德HCl（I）的结晶多晶型物及其制备方法。该应用提供了制备结晶多晶型α-bgr的方法。并且μ基本上不含与工艺相关的杂质。通过根据本发明的方法获得的具有根据图1和2的XRDP图案的芬戈莫德HCl（I）的结晶多晶型物。 1,3和5，其可用作用于治疗或预防包括多发性硬化的自身免疫相关病症的药物组合物中的活性药物成分。

7. 发明申请

US20150315164A1 PROCESS FOR PREPARING AMORPHOUS CABAZITAXEL 审中-公开
标题翻译：制备无定形卡宾的方法
公开(公告)号：US20150315164A1
公开(公告)日：2015-11-05
申请号：US14650296
申请日：2013-12-18
申请人： SHILPA MEDICARE LIMITED
发明人： SRIRAM RAMPALLI , PRASHANT PUROHIT , PRADEEP POTHANA , ANAND KUMAR DUNGA , AKSHAY KANT CHATURVEDI
IPC分类号： C07D305/14 , A61K31/337
CPC分类号： C07D305/14 , A61K31/337
摘要： The present invention provides a process for preparing amorphous Cabazitaxel from the solvate form of Cabazitaxel.The present invention also provides novel diisopropyl ether solvate form of Cabazitaxel (I), and process for preparation thereof.Said amorphous Cabazitaxel and crystalline diisopropyl ether solvate of Cabazitaxel of the present invention can be utilized in preparing the pharmaceutical composition/s useful in the treatment of cancer.
摘要翻译：本发明提供了从卡巴他赛的溶剂合物形式制备无定形卡巴他赛的方法。本发明还提供新的二异丙醚溶剂合物形式的卡巴他赛（I）及其制备方法。本发明的卡马西他定的非卡拉司他和结晶二异丙基醚溶剂合物可用于制备可用于治疗癌症的药物组合物。

8. 发明申请

US20150284421A1 FORMULATION OF 5-AZACYTIDINE 审中-公开
标题翻译： 5-氮杂环丁酮的配方
公开(公告)号：US20150284421A1
公开(公告)日：2015-10-08
申请号：US14441517
申请日：2013-11-08
申请人： Shilpa Medicare Limited
发明人： Pradeep Shivakumar , Nagaraju Dasari , Ravi Kishore , Rizwan Ahmed , Akshaykant Chaturvedi
IPC分类号： C07H19/12
CPC分类号： C07H19/12 , A61K45/06
摘要： The present invention relates to lyophilized formulations comprising crystalline 5-azacytidine and process for preparing lyophilized formulations comprising crystalline 5-azacytidine.
摘要翻译：本发明涉及包含结晶5-氮杂胞苷的冻干制剂和用于制备包含结晶5-氮杂胞苷的冻干制剂的方法。

9. 发明公开

US20240238196A1 FAST DISSOLVING ORAL FILM PREPARATION COMPRISING RIVAROXABAN 审中-公开
公开(公告)号：US20240238196A1
公开(公告)日：2024-07-18
申请号：US18563876
申请日：2022-06-22
申请人： Shilpa Medicare Limited
发明人： SUDHIR VASANTRAO GAMBHIRE , RITESH VINOD BIRLA , TOPPALADODDI KRISHNAMURTHY
IPC分类号： A61K9/00 , A61K31/5377 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/44
CPC分类号： A61K9/0056 , A61K31/5377 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/44
摘要： The present invention relates to an orally fast dissolving film formulation comprising rivaroxaban or pharmaceutically acceptable salts thereof and the process for preparation thereof. The present invention further relates to the fast dissolving film formulation comprising rivaroxaban or a pharmaceutically acceptable salt thereof and at least one solubilizer, wherein the film has high dissolution rate, causes no risk of damage to oral tissues and gives a good feeling, when placed on the tongue.

10. 发明授权

US11857556B2 Topical compositions of dutasteride 有权
公开(公告)号：US11857556B2
公开(公告)日：2024-01-02
申请号：US17239685
申请日：2021-04-26
申请人： Rajendar Medishetty , Agadihiremath Thippeswamy , Sreenivasa Reddy , Shivakumar Pradeep
发明人： Rajendar Medishetty , Agadihiremath Thippeswamy , Sreenivasa Reddy , Shivakumar Pradeep
IPC分类号： A61K31/58 , A61K9/00 , A61P17/14 , A61K47/10 , A61K47/14 , A61K47/44
CPC分类号： A61K31/58 , A61K9/0014 , A61K47/10 , A61K47/14 , A61K47/44 , A61P17/14
摘要： The present invention relates to a composition for topical application for preventing hair loss, androgenic alopecia (AA) and stimulating hair growth having dutasteride. The composition for topical application for preventing hair loss and stimulating hair growth according to the present invention provides equal or superior hair loss prevention and hair growth stimulating effects while using much smaller dosage than the conventional compositions (oral dosage form) which use finasteride and dutasteride.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式